Vol 51, No 2 (2020)
ORIGINAL RESEARCH ARTICLE
Published online: 2020-06-01

open access

Page views 304
Article views/downloads 342
Get Citation

Connect on Social Media

Connect on Social Media

Prognostic impact of Epstein-Barr virus serostatus in patients with nonmalignant hematological disorders undergoing allogeneic hematopoietic cell transplantation: the study of Infectious Diseases Working Party of the European Society for Blood and Marrow Transplantation

Jan Styczynski1, Gloria Tridello2, Lidia Gil3, Per Ljungman4, Malgorzata Mikulska5, Steffie van der Werf6, Nina Simone Knelange6, Diana Averbuch7, Gerard Socié8, Hendrik Veelken9, Jean-Hugues Dalle10, Mahmoud Aljurf11, Alphan Kupesiz12, Yves Bertrand13, Abdelghani Tbakhi14, Boris Afanasyev15, Bruno Lioure16, Hélène Labussière-Wallet17, Xavier Poiré18, Johan Maertens19, Eefke Petersen2021, Patrice Chevallier22, Noel Milpied23, John A. Snowden24, Ibrahim Yakoub-Agha, Jan Cornelissen25, Nicolaas Schaap21, Carlo Dufour26, Regis Peffault de Latour8, Arjan Lankester9, Simone Cesaro2
DOI: 10.2478/ahp-2020-0015
Acta Haematol Pol 2020;51(2):73-80.

Abstract

Background

In patients with acute leukemia, lymphoma and chronic malignancies, donor and/or recipient Epstein-Barr virus (EBV) seropositive status increases the risk of development of chronic graft-versus-host disease (cGVHD) after allo-hematopoietic cell transplantation (allo-HCT), while it has no influence on other transplant outcomes. No data are available on the impact of EBV serostatus on transplant outcomes in patients with nonmalignant hematological disorders.

Objective

We analyzed the influence of the recipient's (R) and donor's (D) EBV serostatus on transplant outcomes (overall survival (OS); relapse-free survival (RFS); relapse incidence (RI); nonrelapse mortality (NRM); acute graft-versus-host disease (aGVHD); cGVHD) in patients with nonmalignant hematological disorders undergoing allo-HCT.

Patients and Methods

A total of 2,355 allo-HCTs performed between 1997 and 2016 for acquired bone marrow failure or hemoglobinopathies were included in this retrospective Registry megafile Infectious Diseases Working Party of the European Society of Blood and Marrow Transplantation (IDWP-EBMT) study.

Results

Array

Conclusions

Allo-HCT from EBV-seropositive versus EBV-seronegative donors are at 31% higher risk of cGVHD in patients with nonmalignant hematological disorders undergoing allo-HCT; however this difference is nonsignificant in multivariate analysis.

Article available in PDF format

View PDF Download PDF file